Oramed Pharmaceuticals Inc. (ORMP) stock
ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.71−0.32 (-7.94%)
Close on Nov 13, 2026Market cap $154.33MP/E 1.1Yield 6.74%
Oramed Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Oramed Pharmaceuticals's gross margin for the twelve months ending Dec 31, 2025 was 0.7%. For fiscal 2025 it was 0.7%, against 96.7% the year before. The highest annual figure on record is 103.5% in fiscal 2018.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0.7% | −96.0 |
| FY2019 | Aug 31, 2019 | 96.7% | −6.8 |
| FY2018 | Aug 31, 2018 | 103.5% | +11.1 |
| FY2017 | Aug 31, 2017 | 92.4% | +68.8 |
| FY2016 | Aug 31, 2016 | 23.6% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | 0.7% | −113.3 |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | 100.0% | +0.0 |
| Q3 FY2019CQ2 2019 | May 31, 2019 | 100.0% | +0.0 |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | 100.0% | +0.0 |
| Q3 FY2018CQ2 2018 | May 31, 2018 | 113.9% | +44.6 |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | 100.0% | +54.0 |
| Q3 FY2017CQ2 2017 | May 31, 2017 | 100.0% | +3.2 |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | 100.0% | – |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | 69.3% | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | 46.0% | – |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | 96.8% | – |
See a number that looks wrong?